276 related articles for article (PubMed ID: 24957246)
1. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.
Alvarez-Larrán A; Ancochea A; García M; Climent F; García-Pallarols F; Angona A; Senín A; Barranco C; Martínez-Avilés L; Serrano S; Bellosillo B; Besses C
Br J Haematol; 2014 Sep; 166(6):911-9. PubMed ID: 24957246
[TBL] [Abstract][Full Text] [Related]
2. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
5. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
6. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
7. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
8. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
9. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
11. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
Dong L; Shen XL; Wei W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
[TBL] [Abstract][Full Text] [Related]
13. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
[TBL] [Abstract][Full Text] [Related]
14. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
17. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
18. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
20. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
